Wright Medical Group Receives Consensus Recommendation of “Buy” from Brokerages (NASDAQ:WMGI)
Shares of Wright Medical Group (NASDAQ:WMGI) have earned an average recommendation of “Buy” from the twelve brokerages that are presently covering the stock, Stock Ratings Network reports. Four analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $35.64.
A number of research firms have recently commented on WMGI. Analysts at Zacks reiterated a “neutral” rating on shares of Wright Medical Group in a research note on Thursday. They now have a $32.00 price target on the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Wright Medical Group in a research note on Wednesday, August 6th. They now have a $40.00 price target on the stock, up previously from $37.00.
Wright Medical Group (NASDAQ:WMGI) opened at 29.86 on Thursday. Wright Medical Group has a 52 week low of $23.70 and a 52 week high of $33.80. The stock’s 50-day moving average is $31.40 and its 200-day moving average is $30.7. The company’s market cap is $1.482 billion.
Wright Medical Group (NASDAQ:WMGI) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.03. The company had revenue of $72.40 million for the quarter, compared to the consensus estimate of $74.17 million. During the same quarter in the previous year, the company posted ($0.34) earnings per share. The company’s revenue for the quarter was up 397.3% on a year-over-year basis. Analysts expect that Wright Medical Group will post $-1.33 EPS for the current fiscal year.
Wright Medical Group, Inc through Wright Medical Technology, Inc (NASDAQ:WMGI) and other operating subsidiaries (Wright), is a global orthopaedic medical device company specializing in the design, manufacture and marketing of devices and biologic products for extremity, hip and knee repair and reconstruction.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.